Here are the 10-Q quarterly reports from Cidara Therapeutics, Inc. (CDTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CDTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDTX filings page.
Cidara Therapeutics (CDTX) reported Q3 2025 results showing a larger operating loss as it advanced its lead antiviral, CD388. The company recorded no revenue and a net loss of $83.2 million, driven by $45.0 million of acquired in‑process R&D and higher R&D spending.
Liquidity strengthened following capital raises. As of September 30, cash and cash equivalents were $293.7 million, with $126.4 million in short‑term and $50.2 million in long‑term available‑for‑sale investments; restricted cash was $6.3 million. In June, the company completed an underwritten offering of 9,147,727 shares at $44.00 per share for net proceeds of $376.9 million, and earlier sold shares via ATM for $4.1 million.
Clinical progress continued. In June, the Phase 2b NAVIGATE study of CD388 met its primary and secondary endpoints across all doses. In September, Cidara initiated the Phase 3 ANCHOR trial evaluating a single 450mg subcutaneous dose for pre‑exposure prophylaxis of seasonal influenza. The company also entered a cost‑reimbursement BARDA contract on September 30. Shares outstanding were 29,335,397 at quarter‑end and 31,439,371 as of November 3, 2025.